Learning outcomes
By the end of this lesson you should be able to: classify the causes of abnormal uterine bleeding by the PALM-COEIN system and by the pattern of bleeding; describe the appropriate investigation of heavy, intermenstrual and post-menopausal bleeding; state the medical, hormonal and surgical treatments of heavy menstrual bleeding and their place; distinguish the red-flag presentations that require urgent referral; and identify the causes of post-menopausal bleeding and the pathway that follows it.
Prerequisites
Lessons 2 and 6 (the menstrual cycle and menstrual disorders), and lesson 1 (anatomy) for the uterus that bleeds. Abnormal uterine bleeding is the commonest gynaecological presentation, and every treatment modifies the cycle.
The big idea
Two distinctions drive everything in this lesson. The first is structural versus non-structural, which is exactly what the PALM-COEIN system expresses: a polyp, adenomyosis, a leiomyoma or a malignancy can be seen and removed, while a coagulopathy, ovulatory dysfunction, an endometrial disorder or an iatrogenic cause is treated by different means altogether. The second is by pattern: heavy regular bleeding, bleeding between periods, and bleeding after the menopause are three different questions with three different causes and three different investigations.
Worked example: PALM-COEIN
| Class | Cause | Comment |
|---|---|---|
| P — Polyp | Endometrial or cervical polyp | Presents with intermenstrual and post-coital bleeding; seen on ultrasound and removed at hysteroscopy |
| A — Adenomyosis | Endometrium within the myometrium | The commonest cause of heavy and painful menstrual bleeding in a parous woman aged 40 to 50, with a bulky, tender uterus |
| L — Leiomyoma | Uterine fibroids | Heavy and prolonged bleeding, pressure on the bladder and bowel, and subfertility; submucous fibroids distort the cavity and are the group that causes bleeding |
| M — Malignancy and hyperplasia | Endometrial and cervical carcinoma | The reason that persistent bleeding must be investigated rather than treated empirically; the endpoint of the pathway |
| Co — Coagulopathy | Von Willebrand disease, thrombocytopenia and anticoagulation | Should be considered when heavy bleeding has been present since menarche, or where there is bruising or epistaxis |
| O — Ovulatory dysfunction | Anovulatory cycles, polycystic ovary syndrome, perimenopause, hypothyroidism | Unopposed oestrogen thickens the endometrium, which then breaks down unpredictably and gives irregular heavy bleeding |
| E — Endometrial | An endometrial cause with no other explanation | Often after oestrogen priming with no progestogenic opposition, and treated by a hormonal method |
| I — Iatrogenic | Hormonal contraception, anticoagulants, an intrauterine device | The levonorgestrel intrauterine device both causes and treats bleeding, and its diagnosis is made by the timing of the onset |
| N — Not yet classified | Chorio-decidual changes, arteriovenous malformation | A small residual group, including rare causes such as uterine arteriovenous malformation |
The pattern of bleeding further narrows the cause. Heavy regular bleeding is heavy menstrual bleeding and is usually ovulatory, and it is caused by structural disease or by endometrial factors; intermenstrual bleeding suggests a polyp, a fibroid, infection, hormonal contraception or cervical disease; and post-coital bleeding suggests a cervical ectropion, a polyp, cervicitis or a malignancy, which is why a woman with post-coital bleeding is examined and her cervix is examined and sampled rather than reassured.
Clinical correlation: investigation
| Investigation | Purpose |
|---|---|
| Full blood count | Anaemia; a haemoglobin below 120 g/L is the finding that converts the treatment from symptomatic to urgent |
| Transvaginal ultrasound | The first-line imaging: the endometrial thickness, the presence of fibroids, polyps and adenomyosis, and the ovaries |
| Endometrial biopsy | To exclude hyperplasia and carcinoma: indicated in all women with bleeding at 45 years or more, and at any age where there are risk factors, persistent bleeding, or an endometrial thickness above the cut-off on ultrasound |
| Hysteroscopy and biopsy | The diagnostic test for a focal lesion such as a polyp or submucous fibroid, and the test where the ultrasound is abnormal or inconclusive |
| Coagulation screen | Where bleeding has been heavy since menarche or where there is a personal or family history of bleeding or bruising |
| Cervical examination and sampling | Where the bleeding is post-coital, intermenstrual, or where the screening is overdue, and to visualise the ectropion, polyp or lesion |
| Thyroid function and prolactin | In the woman with oligomenorrhoea, galactorrhoea or a raised body mass index |
Watch outThe cut-off for post-menopausal bleeding is an endometrial thickness of 4 millimetres or less on transvaginal ultrasound, below which cancer is unlikely. A thickness of more than 4 millimetres, persistent bleeding, or bleeding because of tamoxifen or because of a persistent problem means sampling, whatever the ultrasound says.
Treatment of heavy menstrual bleeding
| Treatment | Mechanism and effect |
|---|---|
| Levonorgestrel intrauterine system | The first-line treatment: it thins the endometrium and reduces menstrual blood loss by about 90 per cent within a year; it also provides contraception and reduces dysmenorrhoea |
| Tranexamic acid | An antifibrinolytic taken on the days of the heaviest bleeding, which reduces blood loss by about half and may be combined with a hormonal method |
| Non-steroidal anti-inflammatory drugs | Mefenamic acid during the period, which reduces the prostaglandin-driven bleeding and also the dysmenorrhoea |
| Combined hormonal contraception | Suppresses the endometrium and gives a regular, light withdrawal bleed, where contraception is also wanted and there is no contraindication |
| Oral progestogens or an injectable progestogen | Thin the endometrium and are used in the woman with anovulatory bleeding and where the oestrogen-containing options are contraindicated |
| Gonadotropin-releasing hormone analogues | Produce a reversible hypo-oestrogenic state that suppress the bleeding entirely, for the woman awaiting surgery or where a prolonged treatment is not an option; add-back hormone replacement is used to prevent bone loss |
| Iron replacement and, where severe, transfusion | For the anaemia, which is often the reason that a woman presents and the thing that must actually be corrected |
| Endometrial ablation | Destroys the endometrium and reduces bleeding to a light or absent flow; offered where the uterus is not large, the woman does not want a pregnancy and no malignancy has been excluded |
| Myomectomy, uterine artery embolisation or hysterectomy | Surgical, for fibroids or where the medical treatments fail; the hysterectomy is definitive and is reserved for the woman whose family is complete |
Why is the levonorgestrel intrauterine system the first-line treatment of heavy menstrual bleeding, and when is it not suitable?
Red flags
| Presentation | Concern | Action |
|---|---|---|
| Post-menopausal bleeding of any amount | Endometrial carcinoma in about 10 per cent of such women | Urgent transvaginal ultrasound and endometrial sampling; a two-week cancer pathway referral |
| Post-coital bleeding | Cervical carcinoma until excluded | Cervical examination and sampling, urgent referral if a lesion is seen |
| Persistent intermenstrual bleeding of new onset | Structural lesion or endometrial pathology | Ultrasound and hysteroscopy |
| Heavy bleeding with a raised body mass index, hypertension, diabetes or polycystic ovary syndrome | Chronic unopposed oestrogen with endometrial hyperplasia and carcinoma | Endometrial biopsy before starting treatment |
| Bleeding with severe anaemia or with symptoms requiring transfusion | The severity of the blood loss itself | Urgent admission and haemoglobin correction |
Watch outEvery post-menopausal bleeding must be investigated, and atrophic change is a diagnosis made after a normal examination, a normal ultrasound and a negative endometrial sample — not before them. Attributing the bleeding to atrophy is the commonest way that endometrial carcinoma is missed.
Common mistakes
Watch outSaying an endometrial biopsy is only needed above the age of 55. It is needed at 45 and above, and at any age where bleeding persists, where there are risk factors, or where a hormonal treatment has not worked — the younger woman with polycystic ovary syndrome is a woman with endometrial cancer risk.
Watch outConfusing heavy menstrual bleeding with anovulatory bleeding. Heavy menstrual bleeding is cyclical, often painful, and ovulatory; anovulatory bleeding is irregular, unpredictable, and caused by unopposed oestrogen, and it is treated with a progestogen rather than an antifibrinolytic.
Watch outSaying tranexamic acid or a non-steroidal anti-inflammatory drug treats the cause of the bleeding. They reduce the volume of the loss; treating the cause means treating the fibroid, the polyp, the endometrium or the anovulation, and reserving surgery for the cause that will not otherwise stop.
Check your understanding
What does PALM-COEIN stand for, and how does it differ from the classification of normal bleeding?
How is post-menopausal bleeding investigated, and what cut-off is used?
Which treatments reduce menstrual blood loss, and by how much?
Multiple choice
Which cervical appearances suggest that a woman's heavy menstrual bleeding is caused by a structural cause?
Which is the first-line treatment of heavy menstrual bleeding in a woman who needs contraception?
What is the endometrial thickness cut-off on transvaginal ultrasound below which endometrial cancer is unlikely in post-menopausal bleeding?
A 36-year-old woman with polycystic ovary syndrome has heavy irregular bleeding. Which endometrial risk should be considered before treating the bleeding?
Which intervention is reserved for the woman whose family is complete and whose bleeding has not responded to medical treatment?
Summary and next
Abnormal uterine bleeding is classified by the structural causes (polyp, adenomyosis, leiomyoma, malignancy) and the non-structural ones (coagulopathy, ovulatory dysfunction, endometrial, iatrogenic, not yet classified), and by the pattern of bleeding, which is the first thing to ask about. Investigation is a full blood count, a transvaginal ultrasound, endometrial sampling where indicated, and hysteroscopy for focal lesions. The levonorgestrel intrauterine system is the first-line treatment of heavy menstrual bleeding, tranexamic acid and non-steroidal anti-inflammatory drugs reduce the flow, and surgery treats the structural cause. Post-menopausal and post-coital bleeding are cancer until excluded, with a 4 millimetre endometrial thickness as the threshold for sampling.